• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特定因素影响自体和同种异体造血干细胞移植的成功。

Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation.

机构信息

Departamento de Análises Clínicas e Toxicológicas, CCS, Universidade Federal de Santa Maria, Santa Maria RS, Brazil.

出版信息

Oxid Med Cell Longev. 2009 Apr-Jun;2(2):82-7. doi: 10.4161/oxim.2.2.8355.

DOI:10.4161/oxim.2.2.8355
PMID:20357929
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2763249/
Abstract

Successful hematopoietic stem cell transplantation (HSCT), both autologous and allogeneic, requires a rapid and durable engraftment, with neutrophil (>500/microL) and platelet (>20,000/microL) reconstitution. Factors influencing engraftment after autologous or allogeneic HSCT were investigated in 65 patients: 25 autologous peripheral stem cell transplantation (PBSCT) and 40 allogeneic bone marrow transplantation (BMT) patients. The major factor affecting engraftment was the graft source for HSCT. Neutrophil and platelet recovery were more rapid in autologous PBSCT than in allogeneic BMT [neutrophil occurring in median on day 10.00 (09.00/11.00) and 19.00 (16.00/23.00) and platelet on day 11.00 (10.00/13.00) and 21.00 (18.00/25.00), respectively; p < 0.0001]. The type of disease also affected engraftment, where multiple myeloma (MM) and lymphoma showed faster engraftment when compared with leukemia, syndrome myelodysplastic (SMD) and aplastic anemia (AA) and MM presented the best overall survival (OS) in a period of 12 months. Other factors included the drug used in the conditioning regimen (CR), where CBV, melphalan (M-200) and FluCy showed faster engraftment and M-200 presented the best OS, in a period of 12 months and age, where 50-59 years demonstrated faster engraftment. Sex did not influence neutrophil and platelet recovery.

摘要

成功的造血干细胞移植(HSCT),无论是自体还是异体,都需要快速和持久的植入,中性粒细胞(>500/μL)和血小板(>20,000/μL)的重建。本研究旨在探讨影响自体和异体 HSCT 后植入的因素。65 例患者接受了研究:25 例自体外周造血干细胞移植(PBSCT)和 40 例异基因骨髓移植(BMT)患者。影响植入的主要因素是 HSCT 的移植物来源。自体 PBSCT 中性粒细胞和血小板恢复较异体 BMT 更快[中性粒细胞中位数分别在第 10 天(9.00/11.00)和第 19 天(16.00/23.00),血小板中位数分别在第 11 天(10.00/13.00)和第 21 天(18.00/25.00)恢复;p<0.0001]。疾病类型也影响植入,多发性骨髓瘤(MM)和淋巴瘤与白血病、骨髓增生异常综合征(SMD)和再生障碍性贫血(AA)相比,植入更快,MM 在 12 个月时总生存(OS)最佳。其他因素包括预处理方案(CR)中使用的药物,CBV、美法仑(M-200)和氟达拉滨(FluCy)的植入更快,M-200 在 12 个月时 OS 最佳,年龄方面,50-59 岁植入更快。性别对中性粒细胞和血小板的恢复没有影响。

相似文献

1
Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation.特定因素影响自体和同种异体造血干细胞移植的成功。
Oxid Med Cell Longev. 2009 Apr-Jun;2(2):82-7. doi: 10.4161/oxim.2.2.8355.
2
Comparisons between allogeneic peripheral blood stem cell transplantation and allogeneic bone marrow transplantation in adult hematologic disease: a single center experience.成人血液系统疾病中异基因外周血干细胞移植与异基因骨髓移植的比较:单中心经验
Kaohsiung J Med Sci. 2003 Nov;19(11):541-8. doi: 10.1016/S1607-551X(09)70504-2.
3
Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.再生障碍性贫血后继发骨髓增生异常综合征和急性髓系白血病患儿和青年进行造血干细胞移植。
Biol Blood Marrow Transplant. 2014 Mar;20(3):425-9. doi: 10.1016/j.bbmt.2013.11.031. Epub 2013 Dec 5.
4
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.非清髓性干细胞移植和细胞疗法作为传统骨髓移植(伴有致死性细胞消减)的替代方法,用于治疗恶性和非恶性血液系统疾病。
Blood. 1998 Feb 1;91(3):756-63.
5
Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population.儿科人群中异基因外周血干细胞移植和骨髓移植后的造血及免疫恢复
Pediatr Transplant. 2002 Aug;6(4):319-26. doi: 10.1034/j.1399-3046.2002.02020.x.
6
Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.干细胞来源对血液系统恶性肿瘤异基因干细胞移植结局的影响。
Vojnosanit Pregl. 2011 Dec;68(12):1026-32.
7
[10 years transplantation of bone marrow and hematopoietic stem cells in adults at the Hannover Medical School].
Med Klin (Munich). 1996 Apr 12;91 Suppl 3:3-17.
8
[Indications, technique and risks in bone marrow transplantation in adulthood].[成人骨髓移植的适应症、技术及风险]
Praxis (Bern 1994). 1996 Mar 19;85(12):378-86.
9
Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia.再生障碍性贫血患者异基因造血干细胞移植前的绝对中性粒细胞计数的意义。
Ann Hematol. 2024 Aug;103(8):3121-3133. doi: 10.1007/s00277-024-05800-1. Epub 2024 May 16.
10
Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.多发性骨髓瘤首次缓解诱导治疗后自体骨髓移植与外周血干细胞移植的比较。
Bone Marrow Transplant. 1995 Jun;15(6):963-9.

引用本文的文献

1
Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.多发性骨髓瘤自体造血干细胞移植后早期疗效及免疫重建分析
Sci Rep. 2025 Jan 7;15(1):1222. doi: 10.1038/s41598-024-84047-2.
2
Predictive factors for engraftment kinetics of autologous hematopoietic stem cells in children.儿童自体造血干细胞植入动力学的预测因素
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S291-S298. doi: 10.1016/j.htct.2024.09.2481. Epub 2024 Nov 7.
3
Urine-derived stem cells serve as a robust platform for generating native or engineered extracellular vesicles.尿液来源的干细胞可作为生成天然或工程细胞外囊泡的强大平台。
Stem Cell Res Ther. 2024 Sep 11;15(1):288. doi: 10.1186/s13287-024-03903-0.
4
Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation.移植时循环髓系来源抑制细胞计数降低是自体造血干细胞移植后多发性骨髓瘤复发的危险因素之一。
Heliyon. 2024 Feb 16;10(5):e26362. doi: 10.1016/j.heliyon.2024.e26362. eCollection 2024 Mar 15.
5
Blood components utilization in hematopoietic stem cell transplantation: Thirteen-year analysis from an apex oncology center of India.造血干细胞移植中血液成分的利用:来自印度一家顶尖肿瘤中心的13年分析
Asian J Transfus Sci. 2023 Jul-Dec;17(2):221-228. doi: 10.4103/ajts.ajts_12_22. Epub 2022 Sep 28.
6
In vivo observation of multi-phase spatiotemporal cellular dynamics of transplanted HSPCs during early engraftment.移植的造血干细胞在早期植入过程中多阶段时空细胞动力学的体内观察
FASEB Bioadv. 2022 May 13;4(8):547-559. doi: 10.1096/fba.2021-00164. eCollection 2022 Aug.
7
A retrospective review of infections and outcomes within 100 days of hematopoietic stem cell transplantation: insights from a new transplant program in the Philippines.造血干细胞移植100天内感染情况及预后的回顾性研究:来自菲律宾一个新移植项目的见解
IJID Reg. 2022 Mar 20;3:101-105. doi: 10.1016/j.ijregi.2022.03.011. eCollection 2022 Jun.
8
Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.重组人血小板生成素可改善新诊断多发性骨髓瘤患者自体造血干细胞移植后的血小板植入。
Cancer Med. 2021 Nov;10(21):7641-7649. doi: 10.1002/cam4.4294. Epub 2021 Sep 26.
9
Eltrombopag post autologous hematopoietic stem cell transplant - an emerging indication in younger pediatric patients.艾曲泊帕用于自体造血干细胞移植后——在低龄儿科患者中一种新出现的适应证。
Am J Blood Res. 2021 Apr 15;11(2):168-171. eCollection 2021.
10
A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes.关于影响造血干细胞移植主要结局的因素的简要综述。
Health Sci Rep. 2021 May 7;4(2):e282. doi: 10.1002/hsr2.282. eCollection 2021 Jun.

本文引用的文献

1
Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.外周血与骨髓作为重型Ⅰ级和Ⅱ级β地中海贫血患儿异基因移植造血干细胞来源的比较
Biol Blood Marrow Transplant. 2008 Mar;14(3):301-8. doi: 10.1016/j.bbmt.2007.12.491.
2
Graft failure after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后的移植物失败
Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):165-70. doi: 10.1016/j.bbmt.2007.10.025.
3
Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia.
Pediatr Transplant. 2008 Feb;12(1):14-9. doi: 10.1111/j.1399-3046.2007.00825.x. Epub 2007 Dec 14.
4
Hematopoietic cell transplantation: progress and obstacles.
Ann Oncol. 2007 Sep;18(9):1450-6. doi: 10.1093/annonc/mdm064. Epub 2007 Mar 12.
5
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.使用基于氟达拉滨的造血细胞移植克服重度输血和同种免疫的骨髓衰竭综合征患者的移植物排斥反应。
Br J Haematol. 2006 May;133(3):305-14. doi: 10.1111/j.1365-2141.2006.06019.x.
6
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.异环磷酰胺、伊达比星和依托泊苷用于复发/难治性霍奇金病或非霍奇金淋巴瘤:一种在自体干细胞移植前具有高缓解率的挽救方案。
Biol Blood Marrow Transplant. 2005 Sep;11(9):688-97. doi: 10.1016/j.bbmt.2005.05.014.
7
Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.氟达拉滨、环磷酰胺加抗胸腺细胞球蛋白预处理方案用于重型再生障碍性贫血的非亲缘骨髓移植
Bone Marrow Transplant. 2004 Dec;34(11):939-43. doi: 10.1038/sj.bmt.1704720.
8
Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation.
Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L706-14. doi: 10.1152/ajplung.00015.2004. Epub 2004 Mar 12.
9
Blood versus marrow hematopoietic allogeneic graft.血液与骨髓造血异体移植物。
Transfus Apher Sci. 2003 Aug;29(1):53-9. doi: 10.1016/S1473-0502(03)00104-6.
10
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.低剂量全身照射(TBI)和氟达拉滨,随后进行来自人类白细胞抗原(HLA)匹配或不匹配的无关供者的造血细胞移植(HCT),并在移植后使用环孢素和霉酚酸酯(MMF)进行免疫抑制,可使血液系统疾病患者诱导出持久的完全嵌合状态并实现持续缓解。
Blood. 2003 Feb 15;101(4):1620-9. doi: 10.1182/blood-2002-05-1340. Epub 2002 Oct 3.